Select Medical (SEM) came out with quarterly earnings of $ 0.37 per share, exceeding Sachs ’consensus estimate of $ 0.29 per share. That’s compared to earnings of $ 0.82 per share a year ago. These figures have been adjusted for unique articles.
This quarterly report represents an unexpected profit of 27.59%. A quarter ago, it was expected that this hospital and rehab center operator would post earnings of $ 0.29 per share, when in fact it received earnings of $ 0.37, which was a surprise of 27.59%.
Over the past four quarters, the company has quadrupled EPS’s consensus estimates.
The sustainability of immediate stock price movements, based on recently released figures and expectations of future earnings, will largely depend on management comments to earnings call.
Since the beginning of the year, shares of Select Medical have lost about 21.3% against the decline of the S&P 500 by -9.8%.
What awaits Select Medical?
Despite the fact that this year’s Select Medical has not yet matured in the market, investors are wondering: what will happen to the stock?
There are no simple answers to this key question, but one reliable measure that can help investors solve this problem is the company’s profit forecast. This not only includes current consensus revenue expectations for the next quarter (s), but also how those expectations have changed recently.
Empirical studies show a strong correlation between upcoming stock movements and trends in earnings revisions. Investors can track such reviews on their own or rely on a tried and tested rating tool such as Zacks Rank, which has an impressive experience using the opportunity to view earnings estimates.
Ahead of that profit release, the trend of revision scores for Select Medical: mixed. While the magnitude and direction of valuation revisions may change following the company’s just-published earnings report, the current status is converted to a Zacks rating of № 3 (Content) for stocks. Thus, in the near future it is expected that the shares will operate in line with the market. You can see The full list of today’s shares of Zacks # 1 rank (strong buy) is here.
It will be interesting to see how estimates change for the coming quarters and the current fiscal year in the coming days. EPS’s current consensus estimate is $ 0.69 with revenue of $ 1.61 billion for the next quarter and $ 2.16 with revenue of $ 6.42 billion for the current fiscal year.
Investors need to keep in mind that the industry’s outlook can also have a significant impact on stock performance. In terms of Industry Rank Zacks, Medical – HMOs are currently in the top 30% of the 250 Industry Zacks. Our study shows that the top 50% of industries included in the Zacks rankings outperform the bottom 50% by more than 2: 1.
Revolution Medicines, Inc. (RVMD), another stock in the wider Zacks Medical sector, has yet to report results for the quarter ended March 2022. The results are expected to be released on May 9.
The company is expected to post a quarterly loss of $ 0.82 per share in its future report, a change from the same period last year of -54.7%. The consensus estimate of EPS for the quarter has not changed in the last 30 days.
Profits from Revolution Medicines, Inc. are expected to make a profit. will be $ 10 million, down 1.3% from the same quarter last year.
Sachs named “Best Choice Twice”
Out of thousands of stocks, 5 Zacks experts each chose their favorite to soar to 100% or more in the coming months. Of these 5, research director Sheraz Mian chooses one of the most explosive.
It is a little-known chemical company that has grown 65% over last year but is still cheap. With relentless demand, high earnings estimates in 2022 and $ 1.5 billion in share buybacks, retail investors could jump at any moment.
This company could rival or outperform other recent Zacks shares, which doubled, like Boston Beer Company, which rose + 143.0% in just over 9 months, and NVIDIA, which rose + 175.9% year-over-year.
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
This article is first published on Source link